May 20, 2020
Mitsubishi Tanabe Pharma America Announces Launch Of The JourneyMate Program, Offering Live Nurse Educational Phone Support For ALS Patients And Caregivers
May 05, 2020
Mitsubishi Tanabe Pharma America Marks Third Anniversary Of FDA Approval And Reports More Than 5,000 Patients With ALS Treated With RADICAVA® (edaravone)
Jun 05, 2019
Morazone (CAS 6536-18-1) Market Research Report, 2019 - ResearchAndMarkets.com
May 06, 2019
MTPA Announces Nationwide Database Of ALS Infusion Services To Help Patients And Caregivers Identify Local Providers
May 03, 2019
Oxford BioDynamics Joins ALS Biomarker Study Sponsored By Mitsubishi Tanabe Pharma America
May 02, 2019
Post-Hoc Analyses of RADICAVA® (edaravone) Studies Show Phase 3 Study Design Minimized ALS Heterogeneity to Improve Trial Efficiency
Apr 11, 2019
Mitsubishi Tanabe Pharma America to Highlight ALS Research Initiatives at 2019 MDA Clinical & Scientific Conference
Feb 06, 2019
Mitsubishi Tanabe Pharma America Announces More Than 3,500 ALS Patients In The U.S. Have Been Treated With RADICAVA® (edaravone)
Nov 28, 2018
Mitsubishi Tanabe Pharma America To Showcase ALS Research At 29th International Symposium On ALS/MND In Glasgow
Nov 15, 2018
Mitsubishi Tanabe Pharma Group Companies To Present New Data On Investigational Oral Formulation Of Edaravone For ALS At 29th International Symposium On ALS/MND
Apr 18, 2018
Mitsubishi Tanabe Pharma America Announces ALS Presentations At American Academy Of Neurology Annual Meeting
Dec 05, 2017
Mitsubishi Tanabe Pharma America to Present Data on RADICAVA® (Edaravone) At 28th International Symposium on ALS/MND in Boston
Nov 30, 2017
Mitsubishi Tanabe Pharma America Announces Addition of RADICAVA® (edaravone) to U.S. Department of Veterans Affairs National Formulary
Aug 08, 2017
First FDA-Approved Treatment For ALS In 22 Years Now Available In U.S.
Jul 25, 2017
MT Pharma America Begins Patient Insurance Benefits Investigation Process in Advance of Availability of RADICAVA(TM) (Edaravone)